Back to Search
Start Over
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
- Source :
- BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, Dipòsit Digital de la UB, Universidad de Barcelona, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, Biology of Blood and Marrow Transplantation, 25(1), 73-85. Elsevier Science, Recercat: Dipósit de la Recerca de Catalunya, Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya), Recercat. Dipósit de la Recerca de Catalunya
- Publication Year :
- 2019
-
Abstract
- The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. We evaluated 1564 adult patients who underwent RIC alloHCT for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS) from 2000 to 2013 using HLA-identical sibling (matched related donor [MRD]) or unrelated donor (URD) peripheral blood graft and received CYSP or TAC with MTX or MMF for GVHD prophylaxis. Primary outcomes of the study were acute and chronic GVHD and overall survival (OS). The study divided the patient population into 4 cohorts based on regimen: MMF-TAC, MMF-CYSP, MTX-TAC, and MTX-CYSP. In the URD group, MMF-CYSP was associated with increased risk of grade II to IV acute GVHD (relative risk [RR], 1.78; P < .001) and grade III to IV acute GVHD (RR, 1.93; P = .006) compared with MTX-TAC. In the URD group, use of MMF-TAC (versus MTX-TAC) lead to higher nonrelapse mortality. (hazard ratio, 1.48; P = .008). In either group, no there was no difference in chronic GVHD, disease-free survival, and OS among the GVHD prophylaxis regimens. For RIC alloHCT using MRD, there are no differences in outcomes based on GVHD prophylaxis. However, with URD RIC alloHCT, MMF-CYSP was inferior to MTX-based regimens for acute GVHD prevention, but all the regimens were equivalent in terms of chronic GVHD and OS. Prospective studies, targeting URD recipients are needed to confirm these results. ispartof: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION vol:25 issue:1 pages:73-85 ispartof: location:United States status: published
- Subjects :
- Male
Transplantation Conditioning
BLOOD
Tissue transplantation
GVHD PROPHYLAXIS
TACROLIMUS
Graft vs Host Disease
Stem cells
Gastroenterology
Empelts de teixits
immune system diseases
hemic and lymphatic diseases
Leukemia
Mycophenolate mofetil
Hematopoietic Stem Cell Transplantation
Drugs
Hematology
Middle Aged
Allogeneic hematopoietic cell transplantation
Allografts
Survival Rate
COMPARING METHOTREXATE
Myeloid leukemia
surgical procedures, operative
Calcineurin inhibitor Tacrolimus
Cyclosporine
Female
TRIAL
Cèl·lules mare
Life Sciences & Biomedicine
Medicaments
Adult
medicine.medical_specialty
Allogeneic transplantation
Leucèmia mieloide
BONE-MARROW
Immunology
Calcineurin Inhibitors
chemical and pharmacologic phenomena
Disease-Free Survival
Article
Myelogenous
Internal medicine
medicine
Humans
Leucèmia limfocítica crònica
Aged
Retrospective Studies
Transplantation
Science & Technology
business.industry
Siblings
STEM-CELL TRANSPLANTATION
Mycophenolic Acid
Graft-versus-host disease prophylaxis
medicine.disease
Tacrolimus
Calcineurin
Reduced-intensity conditioning
Graft-versus-host disease
Methotrexate
Myelodysplastic Syndromes
Chronic lymphocytic leukemia
business
Chronic myelogenous leukemia
Subjects
Details
- Language :
- English
- ISSN :
- 10838791
- Volume :
- 25
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Biology of Blood and Marrow Transplantation
- Accession number :
- edsair.doi.dedup.....b57aec297a44430d0593c405a75fbaaf